Paul Holoye is an Oncology physician affiliated with University Physicians. OpenAlex indexes 56 publications with 1,922 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5401 N G St Ste 3
Mcallen, TX 78504
Telephone
956-217-7000Registry record last updated 30 May 2019.
Industry payments
54 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20254 payments
- Celgene CorporationProgram year20253 payments
- Aveo Pharmaceuticals, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
50%Opioid Agonist50%Hydrocodone-Acetaminophen100%Part D≥13 patientsNervous system
36.4%Opioid Agonist36.4%Morphine Sulfate Er63%Oxycodone Hcl38%Part D<11 patientsCancer & immunology
13.6%Antimetabolite13.6%Hydroxyurea100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Spontaneous Pneumocephalus Associated With Recurrent Colorectal Carcinoma
Journal of Clinical Oncology
2008 - Phase II clinical trial of didemnin B in previously treated small cell lung cancer
Investigational New Drugs
1994 - Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma
Investigational New Drugs
1992
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”